SCHEMBL5771570

SCHEMBL5771570

CC(=O)c1cc2cc(O)c(C)c(C)c2o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
RECQL P46063 1/20 0.47
ALDH1A1 P00352 4/20 0.45
GAA P10253 3/20 0.45
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 2/20 0.45
GLA P06280 1/20 0.45
CASP1 P29466 1/20 0.45
BRCA1 P38398 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPT P10636 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 1/20 0.40
ALOX12 P18054 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
STAT3 P40763 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772064 0.86 PIM1 (0.46) LMNAKDM4EKMT2AGPR35TP53
SCHEMBL5770807 0.81 MAPT (0.46) LMNARECQLALDH1A1GAAKDM4E
SCHEMBL5892600 0.77 LMNA (0.47) LMNARECQLALDH1A1GAAKDM4E
SCHEMBL499329 0.77 CA9 (0.50) LMNARECQLALDH1A1GAAKDM4E
SCHEMBL5768892 0.77 PDE7B (0.41) LMNAALDH1A1KDM4EHSD17B10HPGD
SCHEMBL5772217 0.75 RAB9A (0.49) ALDH1A1HPGDKMT2AMEN1L3MBTL1
SCHEMBL1896215 0.73 LMNA (0.66) LMNARECQLALDH1A1GAAKDM4E
SCHEMBL11684435 0.73 LMNA (0.45) LMNARECQLALDH1A1GAAKDM4E
SCHEMBL5773853 0.73 MAPT (0.38) LMNARECQLALDH1A1KDM4EHSD17B10
SCHEMBL14668173 0.72 ALDH1A1 (0.43) LMNARECQLALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1472241-A4 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2005-06-29 EP claimed
EP-1472241-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-03 EP claimed
US-6653346-B1 Amtiischemic and antiinflammatory agents GALILEO PHARMACEUTICALS, INC. 2003-11-25 US claimed
WO-2003066618-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2003-08-14 WO claimed
EP-1732903-A1 TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD AstraZeneca AB (SE) 2006-12-20 EP disclosed
US-7078541-B2 Benzofuran derivatives GALILEO PHARMACEUTICALS, INC. (US) 2006-07-18 US disclosed
WO-2005095362-A1 TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD ASTRAZENECA AB (SE) 2005-10-13 WO disclosed
EP-1472241-A4 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2005-06-29 EP disclosed
WO-2005027900-A1 BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed
EP-1472241-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-03 EP disclosed
US-20040063975-A1 Benzofuran derivatives EDISON PHARMACEUTICALS, INC. 2004-04-01 US disclosed
US-6653346-B1 Amtiischemic and antiinflammatory agents GALILEO PHARMACEUTICALS, INC. 2003-11-25 US disclosed
WO-2003066618-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063975-A1 Benzofuran derivatives NDUFAB1, AIFM1, NDUFAF1 LMNA 1138/4885RECQL 1553/4885ALDH1A1 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.